Payment overview · 2025
General Payments
$3,728.18
33 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Joseph Schmidt, MD
Allopathic & Osteopathic Physicians|Family Medicine · ST MARYS, PA · NPI 1780688481
Verified facts
What the public records show
CMS Open Payments records show Robert Joseph Schmidt, MD received $3,728.18 in general payments during 2025 across 33 reported records.
Amgen Inc. accounted for 88.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $3,288.50 | 88.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $184.55 | 5.0% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.52 | 3.9% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.01 | 0.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.67 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.92 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.51 | 0.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.50 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,200.00 | 2 |
| Food and Beverage | $528.18 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $3,273.68 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $132.41 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $64.57 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.14 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.65 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 624 | 165 |
| Metformin Hcl Er | Metformin Hcl | 383 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 75 |
| Potassium Chloride | Potassium Chloride | 263 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 74 |
| Lisinopril | Lisinopril | 215 | 60 |
| Tramadol Hcl | Tramadol Hcl | 210 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 198 | 28 |
| Alprazolam | Alprazolam | 175 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 48 |
| Gabapentin | Gabapentin | 166 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 47 |
| Famotidine | Famotidine | 155 | 38 |
| Metformin Hcl | Metformin Hcl | 148 | 39 |
| Omeprazole | Omeprazole | 148 | 33 |
| Trazodone Hcl | Trazodone Hcl | 135 | 28 |
| Losartan Potassium | Losartan Potassium | 133 | 34 |
| Ezetimibe | Ezetimibe | 130 | 34 |
| Simvastatin | Simvastatin | 130 | 32 |
| Eliquis | Apixaban | 123 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 118 | 31 |
| Jardiance | Empagliflozin | 117 | 29 |
| Valsartan | Valsartan | 111 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 29 |
| Finasteride | Finasteride | 106 | 32 |
| Irbesartan | Irbesartan | 104 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 25 |
| Montelukast Sodium | Montelukast Sodium | 91 | 26 |
| Repatha Sureclick | Evolocumab | 83 | 12 |
| Buspirone Hcl | Buspirone Hcl | 80 | 15 |
| Ozempic | Semaglutide | 79 | 15 |
| Pregabalin | Pregabalin | 79 | 11 |
| Sertraline Hcl | Sertraline Hcl | 78 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 19 |
| Trulicity | Dulaglutide | 71 | suppressed |
| Allopurinol | Allopurinol | 70 | 21 |
| Warfarin Sodium | Warfarin Sodium | 67 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 13 |
| Bumetanide | Bumetanide | 61 | 16 |
| Glimepiride | Glimepiride | 61 | 16 |
| Furosemide | Furosemide | 59 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 18 |
| Donepezil Hcl | Donepezil Hcl | 58 | suppressed |
| Spironolactone | Spironolactone | 58 | 13 |
| Baclofen | Baclofen | 57 | 12 |
| Farxiga | Dapagliflozin Propanediol | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 13 |
| Carvedilol | Carvedilol | 54 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 13 |
| Topiramate | Topiramate | 54 | 13 |
| Meloxicam | Meloxicam | 53 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 51 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 11 |
| Atenolol | Atenolol | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 13 |
| Alendronate Sodium | Alendronate Sodium | 46 | 15 |
| Azithromycin | Azithromycin | 45 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | 12 |
| Eszopiclone | Eszopiclone | 43 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 19 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Prednisone | Prednisone | 41 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 15 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 24 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 26 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Nucynta | Tapentadol Hcl | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 16 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,728.18 · 33 records | Amgen Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, EVENITY, FARXIGA, GVOKE HYPOPEN, LEQVIO, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error